Announcement PDF RNS Number : 2621K Shield Therapeutics PLC 30 June 2026 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Block Listing 6 Monthly Return Name of applicant: SHIELD THERAPEUTICS PLC Name of scheme: Shield Therapeutics Retention Share Plan Period of return: From: 01 January 2026 To: 30 June 2026 Balance of unallotted securities under scheme(s) from previous return: 39,794 Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): NIL Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): NIL Equals: Balance under scheme(s) not yet issued/allotted at end of period: 39,794 Name of applicant: SHIELD THERAPEUTICS PLC Name of scheme: Shield Therapeutics plc 2016 Company Share Option Plan Period of return: From: 01 January 2026 To: 30 June 2026 Balance of unallotted securities under scheme(s) from previous return: 341,020 Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): NIL Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): NIL Equals: Balance under scheme(s) not yet issued/allotted at end of period: 341,020 Name of applicant: SHIELD THERAPEUTICS PLC Name of scheme: The Shield Therapeutics plc 2016 Long Term Incentive Plan Period of return: From: 01 January 2026 To: 30 June 2026 Balance of unallotted securities under scheme(s) from previous return: 24,273 Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): NIL Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): NIL Equals: Balance under scheme(s) not yet issued/allotted at end of period: 24,273 Name of applicant: SHIELD THERAPEUTICS PLC Name of scheme: Shield Therapeutics Retention and Performance Share Plan Period of return: From: 01 January 2026 To: 30 June 2026 Balance of unallotted securities under scheme(s) from previous return: 11,720,965 Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): NIL Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 2,023,801 Equals: Balance under scheme(s) not yet issued/allotted at end of period: 9,697,164 Name of contact: Lucy Huntington-Bailey Telephone number of contact: +44 (0) 191 511 8500 For further information please contact: Shield Therapeutics plc www.shieldtherapeutics.com Anders Lundstrom, CEO Lucy Huntington-Bailey, Company Secretary +44 (0) 191 511 8500 info@shieldtx.com Nominated Adviser and Joint Broker Peel Hunt LLP James Steel +44 (0)20 7418 8900 Joint Broker Cavendish Ltd Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward +44 (0)20 7220 0500 About Iron Deficiency and ACCRUFeR®/FeRACCRU® Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak). ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well- tolerated therapy in a range of clinical trials. More information about ACCRUFeR®/FeRACCRU®, including the product label, can be found at: www.accrufer.com and www.feraccru.com. About Shield Therapeutics plc Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFeR® in the U.S. to include pediatric patients 10 years of age and older with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK and European Union by Norgine B.V., to include pediatric patients 12 years of age and older and also have marketing rights in Australia and New Zealand. FeRACCRU® is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR®/FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan. ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s. ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END MSCFLMMTMTJTTJF